Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l-amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model.
Endoplasmic reticulum (ER) stress caused by accumulation of misfolded proteins is observed in several kinds of diseases. Since ER stress is reported to be involved in the progression of non-alcoholic steatohepatitis (NASH), highly sensitive and simple measurement methods are required for research into developing novel therapy for NASH. To investigate the involvement of ER stress in NASH pathogenesis in a mouse model, an assay for liver ER stress was developed using ER stress activated indicator-luciferase (ERAI-Luc) mice. To establish the assay method for detection of ER stress in the liver, tunicamycin (TM) (0.3 mg/kg i. p.) was administered to ERAI-Luc mice, and the luciferase activity was measured in ex vivo and in vivo. To evaluate ER stress in the NASH model, ERAI-Luc mice were fed a modified choline-deficient l-amino acid-defined (mCDAA) diet for 14 weeks. After measurement of ER stress by luminescence imaging, levels of liver lipids and pro-fibrotic and pro-inflammatory gene expression were measured as NASH-related indexes. In non-invasive whole-body imaging, TM elevated luciferase activity in the liver, induced by activation of ER stress. The highest luminescence in the liver was confirmed by ex vivo imaging of isolated tissues. In parallel with progression of NASH, elevated luminescence induced by ER stress in liver was observed in mCDAA diet-fed ERAI-Luc mice. Luciferase activity was significantly and positively correlated to levels of triglyceride and free cholesterol in the liver, as well as to the mRNA expression of type 1 collagen α1 chain and tumor necrosis factor α. These data indicated that the use of ERAI-Luc mice was effective in the detection of ER stress in the liver. Moreover, the NASH model using ERAI-Luc mice can be a useful tool to clarify the role of ER stress in pathogenesis of NASH and to evaluate effects of drugs targeted against ER stress.
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: you.muraki@takeda.com.
Yo
Y
Muraki
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: yukimasa.makita@takeda.com.
Yukimasa
Y
Makita
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: midori.yamasaki@takeda.com.
Midori
M
Yamasaki
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: yuichiro.amano@takeda.com.
Yuichiro
Y
Amano
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: takanori.matsuo@takeda.com.
Takanori
T
Matsuo
D000818:Animals; D001681:Biological Assay; D002784:Cholesterol / Q000378:metabolism; D002796:Choline Deficiency / Q000209:etiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D024042:Collagen Type I / Q000235:genetics* / Q000378:metabolism; D000090602:Collagen Type I, alpha 1 Chain; D004195:Disease Models, Animal; D004721:Endoplasmic Reticulum / Q000378:metabolism / Q000473:pathology; D059865:Endoplasmic Reticulum Stress / Q000235:genetics*; D005526:Food, Formulated / Q000009:adverse effects*; D005786:Gene Expression Regulation; D017930:Genes, Reporter; D022781:Hepatocytes / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008163:Luminescent Measurements; D051379:Mice; D008810:Mice, Inbred C57BL; D065626:Non-alcoholic Fatty Liver Disease / Q000209:etiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction; D014280:Triglycerides / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics* / Q000378:metabolism; D014415:Tunicamycin / Q000494:pharmacology
D024042:Collagen Type I; D000090602:Collagen Type I, alpha 1 Chain; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D014415:Tunicamycin; D002784:Cholesterol; D008156:Luciferases
Endoplasmic reticulum stress; Endoplasmic reticulum stress activated indicator-luciferase mice; In vivo imaging; Non-alcoholic steatohepatitis